Synerex Pharmaceuticals

Synerex Pharmaceuticals is a specialty pharmaceutical company based in Taiwan that focuses on the development and commercialization of complex generic drugs and innovative drug delivery systems. The company specializes in liposomal formulations and nano-emulsion technologies designed to improve the therapeutic index of established drugs, particularly in oncology and infectious diseases. Synerex has successfully brought products like Lipo-AB (amphotericin B liposome) and Lipo-Dox (doxorubicin liposome) to market, targeting high-barrier therapeutic segments. By leveraging its proprietary technology platforms, the company aims to address unmet medical needs through the 505(b)(2) regulatory pathway. Synerex is publicly traded on the Taipei Exchange and maintains a strategic focus on expanding its product portfolio in global markets, including the United States and Asia.